The ME Association has been discussing this immunological treatment, and ways of advancing this research, with Professor Lars Lagerstrand (Karolinska University Hospital, Stockholm) and he has asked if we could place this announcement on our website.
More information on the vaccine being referred to, including medical references to clinical trials that have taken place, can be found in section 7:3 (Immunological treatments) of ‘ME/CFS/PVFS – An Exploration of the Key Clinical Issues’. If you wish to contact Professor Lagerstrand please do so directly – his email address is provided below.
Message from Professor Lagerstrand:
I am a medical doctor and associate professor working at the Karolinska University Hospital in Stockholm and a member of the committee of the Swedish Association for ME patients in Stockholm. However, I am also a patient with ME/chronic fatigue syndrome since 14 years and have been successfully treated with a vaccine against staphylococcus during the last 8 years.
A Swedish research group has developed a treatment against ME/CFS that reduces symptoms significantly. In Sweden we have about one hundred and fifty patients with ME/CFS that have been successfully treated with a vaccine against staphylococcus. The vaccine has been given to us monthly during 5-10 years without any adverse effects. The treatment has made it possible for the majority of us to work and also to have energy left for our families, friends and even sports and outdoor life. The effectiveness of the vaccine has been proven in a double blind scientific study.
However the vaccine is not produced anymore and most of us have been forced back to illness life. We have thus come to an absurd situation where there exists a treatment of ME/CFS, which could dramatically reduce symptoms and make life much better for millions of people all over the world. It could also reduce the cost of health insurance and probably give a clever financier millions, but perhaps no further development will be done. As far as I can see this is the only possible treatment that could help us within a not too distant future.
We want to spread the information internationally about this treatment among patients, patient organizations and interested doctors as we hope that this could contribute to get a discussion going about how to get resources to develop the treatment. We need help to convince a vaccine manufacturer to start a new vaccine production that makes further research possible. We would also be pleased if someone has contacts or other ideas that could help to solve this problem.
Lars Lagerstrand MD, PhD
Associate Professor, Karolinska University, Stockholm